Xeris Biopharma Holdings (NASDAQ:XERS) CEO Paul Edick joined Steve Darling to share news about the company that commercializing therapies for the patient populations in endocrinology, neurology, and gastroenterology. Edick telling Proactive more about their 3 products currently in the market and he also shares details about their pipeline which is has a interesting drug on in it.
Xeris Biopharma addressing unique needs with 3 products in the market and a strong pipeline
